Pharma News

Join WhatsApp Channel 

Crack GPAT — Prepare for GPAT Online 

Get the latest news from world and India’s leading pharmaceutical companies Pharma Industry, pharmaceutical marketing, generic drugs, and Complete news for Pharmacy and Life Sciences professionals.

  • AstraZeneca’s All-Oral Calquence Combo Wins US FDA Approval
    23 February 2026

    AstraZeneca’s All-Oral Calquence Combo Wins US FDA Approval

    AstraZeneca announced that the U.S. Food and Drug Administration has approved its fixed-duration all-oral combination of Calquence® (acalabrutinib) with venetoclax for the first-line treatment of chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) in adults. The approval marks the first time a Bruton’s tyrosine kinase (BTK) inhibitor-based regimen has been authorised in the U.S. as a time-limited, oral treatment option for newly diagnosed patients.

  • 23 February 2026
    Sai Life Sciences Plans to Hire 700+ Professionals in FY27 Amid Growth Surge

    Sai Life Sciences Limited has announced an ambitious recruitment drive to hire more than 700 scientific, technical and management professionals in the 2026–27 financial year as it scales up operations to meet growing global demand for drug discovery, development and manufacturing services.

  • 23 February 2026
    Gilead Sciences Moves to Acquire Arcellx in USD 7.8B Deal to Fully Harness Anito-cel Potential

    Gilead Sciences today announced a definitive agreement to acquire Arcellx in a transaction valued at approximately USD 7.8 billion, marking a major step in Gilead’s expansion in next-generation cell therapy.

  • 23 February 2026
    European Commission Clears Ranluspec®, Strengthening Sandoz’s Ophthalmology Biosimilars Portfolio
    Sandoz has announced that the European Commission has granted marketing authorization for Ranluspec® (ranibizumab), a biosimilar developed by Lupin. The approval marks a significant step in expanding access to advanced ophthalmic therapies across Europe.
  • 21 February 2026
    New Blood Cancer Treatment Gets US Approval

    The U.S. Food and Drug Administration (FDA) has approved a new cancer treatment combining acalabrutinib (Calquence) and venetoclax for adults with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). This decision makes it the first all-oral, fixed-duration therapy available for patients who have not had prior treatment.

  • 17 February 2026
    ICMR Study Shows Shorter Oral Regimens for Drug-Resistant TB Are Cost-Effective for India’s Health System

    A recent study led by the Indian Council of Medical Research (ICMR) has found that shorter, all-oral treatment regimens for multidrug-resistant and rifampicin-resistant tuberculosis (MDR/RR-TB) could deliver better health outcomes at lower costs compared to longer traditional therapies in India.

  • 17 February 2026
    Lupin Expands Canada Specialty Portfolio with Spektus Deal for DeslaFlex
    Global pharmaceutical company Lupin Limited has entered into a licensing and supply agreement with Spektus Pharma to commercialize DeslaFlex in Canada, marking a strategic move to strengthen its central nervous system (CNS) portfolio in the region.
  • 17 February 2026
    Lilly Eyes India as Strategic Export Base as Mounjaro Demand Surges
    Eli Lilly and Company is strengthening its presence in India and evaluating the country as a strategic export base amid rising demand for its blockbuster diabetes and weight-loss therapy Mounjaro, as reported by Reuters.
  • 13 February 2026
    Vegan Diet May Cut Insulin Needs in Type 1 Diabetes
    A new study published in BMC Nutrition suggests that a low-fat vegan diet may significantly reduce daily insulin requirements for people living with type 1 diabetes potentially lowering treatment costs as well.
  • 12 February 2026
    SEC Seeks Protocol Changes in Zydus Phase III Trial for MMR Vaccine
    The Subject Expert Committee (SEC) on Vaccines has asked Zydus Lifesciences Ltd. to revise its Phase III clinical trial protocol for its Measles, Mumps and Rubella (MMR) Vaccine (Live) I.P. (Freeze Dried). The meeting was held on 29 January 2026 in hybrid mode to review biological and PAC proposals and to advise the Drugs Controller General (India).
Subscribe to Pharma News